OATD-01
Idiopathic Pulmonary Fibrosis (IPF)
Key Facts
About Molecure
Molecure is a clinical-stage biotech with a mission to develop novel small molecule drugs for high-unmet-need diseases in oncology and inflammation. Its key achievement is building two proprietary discovery platforms targeting RNA and protein-protein interactions (PPIs), translating into a maturing internal pipeline. The company's strategy involves advancing its lead programs through clinical proof-of-concept while leveraging its platforms for new discovery and potential partnerships. Its 2021 IPO on the Warsaw Stock Exchange provided capital to execute this strategy and establish Poland as a hub for innovative drug discovery.
View full company profileAbout Molecure
Molecure is a clinical-stage biotech with a mission to develop novel small molecule drugs for high-unmet-need diseases in oncology and inflammation. Its key achievement is building two proprietary discovery platforms targeting RNA and protein-protein interactions (PPIs), translating into a maturing internal pipeline. The company's strategy involves advancing its lead programs through clinical proof-of-concept while leveraging its platforms for new discovery and potential partnerships. Its 2021 IPO on the Warsaw Stock Exchange provided capital to execute this strategy and establish Poland as a hub for innovative drug discovery.
View full company profileAbout Molecure
Molecure is a clinical-stage biotech with a mission to develop novel small molecule drugs for high-unmet-need diseases in oncology and inflammation. Its key achievement is building two proprietary discovery platforms targeting RNA and protein-protein interactions (PPIs), translating into a maturing internal pipeline. The company's strategy involves advancing its lead programs through clinical proof-of-concept while leveraging its platforms for new discovery and potential partnerships. Its 2021 IPO on the Warsaw Stock Exchange provided capital to execute this strategy and establish Poland as a hub for innovative drug discovery.
View full company profileTherapeutic Areas
Other Idiopathic Pulmonary Fibrosis (IPF) Drugs
| Drug | Company | Phase |
|---|---|---|
| FP-020 (BMS-986235) | Foresee Pharmaceuticals | Phase 2 |
| Buloxibutid (C21) | Vicore Pharma | Phase 2b |
| AP02 | Avalyn Pharmaceuticals | Phase 2 |
| Gento-Fibrose Pulmonaire Program | Genoscience Pharma | Preclinical |
| SM001 (alidornase/Tigerase) | SarcoMed USA | Research |
| NLM-001 | Nelum Pharma | Phase 1 |
| GNS-3545 (ROCK2 Inhibitor) | Genosco | Phase 1 |
| TG2 Inhibitor Program | Isterian Biotech | Preclinical |
| Taladegib (ENV-101) | Endeavor BioMedicines | Phase 2b |
| CAL101 | Calluna Pharma | Phase 2 |
| NVP-13 | Velvio | Pre-clinical |
| LASN01 | Lassen Therapeutics | Preclinical |